Literature DB >> 3896483

Ifosfamide--pharmacology, safety and therapeutic potential.

W P Brade, K Herdrich, M Varini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3896483     DOI： 10.1016/0305-7372(85)90011-8

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  58 in total

1.  Basic principles in preclinical cancer chemotherapy.

Authors:  N Brock; J Pohl; B Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.

Authors:  L D Lewis; D L Fitzgerald; P Mohan; N Thatcher; P G Harper; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 3.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

4.  The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump.

Authors:  J A Radford; J M Margison; R Swindell; M J Lind; P M Wilkinson; N Thatcher
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

5.  A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.

Authors:  T Langenbuch; K Mross; W Jonat; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil.

Authors:  A Ghavamzadeh
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Carboplatin and ifosfamide in ovarian cancer phase II and III trials. London Gynaecological Oncology Group.

Authors:  E Wiltshaw; T J Perren; I D Fryatt; P R Blake; P Harper; M Slevin
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Ifosfamide combination chemotherapy in advanced breast cancer.

Authors:  H Schmid; M Kaufmann; E M Grischke; G Bastert
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours.

Authors:  W Hoffmann; B Weidmann; F Migeod; J Könner; S Seeber
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  Ifosfamide may be safely used in patients with end stage renal disease on hemodialysis.

Authors:  Sheron Latcha; Robert G Maki; Gary K Schwartz; Carlos D Flombaum
Journal:  Sarcoma       Date:  2010-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.